The Recall Desk
HighFDA (Devices)·Z-0342-2023·Announced 2022-12-07

CMV IgM EIA Diagnostic Test Recalled for Increased False Positives

Bio-Rad Laboratories is recalling 180 CMV IgM EIA diagnostic test kits due to unusually high rates of false positive results. The recall affects test kits distributed in 14 U.S. states.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: This is an FDA Class II medical device recall involving diagnostic inaccuracy. The test produces increased false positive results with no reported patient illnesses or injuries. Per the severity rubric, this represents a risk-of-harm product where injury has not yet been reported, warranting a score of 3 (High).

Plain-English summary

Bio-Rad Laboratories, Inc. is recalling 180 kits of its CMV IgM EIA (Enzyme Immunoassay), an in vitro diagnostic test used to detect cytomegalovirus (CMV) IgM antibodies. The FDA classified this as a Class II recall.

The test kits are being recalled due to an unusual increase in the positivity rate. This means the test is reporting positive results at higher rates than expected, potentially producing false positive results that could lead to incorrect patient diagnoses.

The affected test kits bear catalog number 25178 and lot numbers B02022, E10022, and G05022. These kits were distributed in 14 U.S. states: California, Colorado, Florida, Georgia, Hawaii, Iowa, Massachusetts, Minnesota, North Carolina, New Hampshire, New Jersey, Pennsylvania, Tennessee, and Texas.

The recalled product

Product
CMV IgM EIA, in vitro diagnostic.
Manufacturer
Bio-Rad Laboratories, Inc.
Hazard
  • false-positive
  • diagnostic-inaccuracy

Distribution

Distributed in 14 states:

  • CA
  • CO
  • FL
  • GA
  • HI
  • IA
  • MA
  • MN
  • NC
  • NH
  • NJ
  • PA
  • TN
  • TX